Magnolia Bark — Research Profile

Relora is a patented combination extract of Magnolia officinalis bark and Phellodendron amurense bark, standardized for honokiol, magnolol, and berberine. It was specifically developed for stress management and has been used in the most rigorous clinical trials — Talbott et al. (2013) demonstrated a significant 18% reduction in salivary cortisol in a 6-week RCT ^[1]. Pure magnolia bark extract contains only the Magnolia-derived compounds (honokiol and magnolol), which act as positive allosteric modulators of GABA-A receptors ^[2]. Both are effective, but Relora has more clinical validation for cortisol reduction.

Clinical studies of up to 6 weeks show good tolerability with no significant adverse effects. Long-term safety data beyond this period is limited. Unlike benzodiazepines, magnolia bark compounds do not appear to cause dependence or tolerance in preclinical studies, and they have been used in traditional Chinese medicine for centuries. However, periodic breaks are prudent given the limited long-term clinical data.

Magnolia bark can be combined with non-GABAergic sleep supplements like melatonin, 5-HTP, or tart cherry. Use caution when combining with other GABA-modulating supplements (valerian, kava, passionflower) as effects may be additive. Start with lower doses of each when combining. Avoid combining with prescription sleep medications or benzodiazepines without medical supervision.

Nearly all clinical evidence uses oral capsules of standardized bark extract, most often the Magnolia-Phellodendron (Relora) combination at 250 mg three times daily. No study has compared different magnolia forms head-to-head, and reference sources say there is not enough evidence to define an optimal preparation, so the capsule extracts used in trials are the most defensible option.

The best-supported effect is a modest reduction in short-term ("state") anxiety and stress: a 6-week trial cut transitory anxiety versus placebo (p=0.045), and a 4-week trial lowered salivary cortisol by about 18% with improved mood scores. Both used the Relora blend, and authoritative reference sources still rate all magnolia uses, including anxiety and weight loss, as having insufficient evidence; the GABA-A receptor activity behind these effects has only been shown in laboratory models.

Clinical trials of the Relora blend used 250 mg three times daily, roughly 750 mg per day, for 4 to 6 weeks. No official dose exists for magnolia bark on its own, and reference sources state there is not enough evidence to establish a dose range, so the trial regimen is the most reliable guide.

The Relora trials split the dose across three times through the day rather than at one fixed time, and no study has compared morning versus evening dosing. Because the honokiol and magnolol in magnolia are sedating, people using it for sleep often take a dose in the evening, but this timing has not been directly tested against alternatives.

In the 6-week trial, adverse effects that led two participants to withdraw included heartburn, hand tremor, and numbness. Reference sources additionally list shaking hands, sexual problems, and thyroid problems, though a causal link is unclear, and drowsiness is expected given magnolia's CNS-depressant GABA-A activity.

Yes. Magnolia can add to the effect of sedatives, benzodiazepines, other CNS depressants, and alcohol, raising the risk of excessive drowsiness, consistent with its GABA-A modulating action. It may also increase bruising and bleeding when taken with anticoagulant or antiplatelet drugs, and reference sources advise stopping it at least 2 weeks before scheduled surgery.

It is best studied in otherwise-healthy adults seeking short-term relief of everyday stress or state anxiety, where the Relora blend produced modest benefits over 4 to 6 weeks. It should be avoided during pregnancy (magnolia may trigger uterine contractions), while breastfeeding, in the two weeks before surgery, and by anyone taking sedatives or blood thinners.

In a 6-week trial of the Magnolia-Phellodendron blend (Relora), transitory ("state") anxiety was significantly lower than placebo by the end of dosing, while a separate 4-week study showed reduced cortisol and improved mood by week 4. Its honokiol and magnolol content acts on GABA-A receptors, which could produce acute calming, but a specific time-to-effect has not been directly measured, so plan on several weeks of daily use to judge benefit.

Long-term safety is not established: the controlled trials of the Magnolia-Phellodendron blend ran only 4 to 6 weeks, and reference sources rate magnolia as only "possibly safe" for short-term use, noting that safety beyond 6 weeks is unknown. If you use it for extended periods, do so cautiously and reassess, since no data support continuous daily intake past a few weeks.

No toxic threshold or upper limit has been defined, and authoritative sources say there is not even enough evidence to set a normal dose range. Because honokiol and magnolol act as CNS-depressant GABA-A modulators, the most likely effect of excess is drowsiness; side effects reported in trials at ordinary doses included heartburn and hand tremor.

The main caution is additive sedation: combining magnolia with other calming or GABAergic supplements could deepen drowsiness, consistent with its GABA-A modulation and its documented additive effect with sedatives and alcohol. Note that most human data come from the fixed Magnolia officinalis-Phellodendron amurense (Relora) combination rather than from magnolia stacked with unrelated supplements, so those pairings are largely untested.

Human evidence is strongest for the standardized Magnolia officinalis-Phellodendron amurense blend (Relora) dosed at 250 mg three times daily, so a product matching that specification is the best-supported choice. Otherwise, look for a bark extract that states its honokiol and magnolol content, since those are the active compounds and no official potency standard exists for magnolia.